These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 15131056

  • 1. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL, Winski SL, Ross D.
    Clin Cancer Res; 2004 May 01; 10(9):3147-55. PubMed ID: 15131056
    [Abstract] [Full Text] [Related]

  • 2. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1509-16. PubMed ID: 11377380
    [Abstract] [Full Text] [Related]

  • 3. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
    Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D.
    Mol Pharmacol; 2008 Dec 15; 74(6):1657-65. PubMed ID: 18794327
    [Abstract] [Full Text] [Related]

  • 4. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL, Hargreaves RH, Butler J, Ross D.
    Clin Cancer Res; 1998 Dec 15; 4(12):3083-8. PubMed ID: 9865924
    [Abstract] [Full Text] [Related]

  • 5. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
    Dehn DL, Inayat-Hussain SH, Ross D.
    J Pharmacol Exp Ther; 2005 May 15; 313(2):771-9. PubMed ID: 15665137
    [Abstract] [Full Text] [Related]

  • 6. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
    Tudor G, Alley M, Nelson CM, Huang R, Covell DG, Gutierrez P, Sausville EA.
    Anticancer Drugs; 2005 Apr 01; 16(4):381-91. PubMed ID: 15746574
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
    Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RH, Butler J.
    Clin Cancer Res; 2005 Apr 01; 11(7):2695-701. PubMed ID: 15814651
    [Abstract] [Full Text] [Related]

  • 9. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
    Digby T, Leith MK, Thliveris JA, Begleiter A.
    Cancer Chemother Pharmacol; 2005 Sep 01; 56(3):307-16. PubMed ID: 15877230
    [Abstract] [Full Text] [Related]

  • 10. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Mol Pharmacol; 2006 Oct 01; 70(4):1194-203. PubMed ID: 16825487
    [Abstract] [Full Text] [Related]

  • 11. Role of NADPH cytochrome P450 reductase in activation of RH1.
    Begleiter A, Leith MK, Patel D, Hasinoff BB.
    Cancer Chemother Pharmacol; 2007 Oct 01; 60(5):713-23. PubMed ID: 17256129
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress.
    Nemeikaite-Ceniene A, Sarlauskas J, Anusevicius Z, Nivinskas H, Cenas N.
    Arch Biochem Biophys; 2003 Aug 01; 416(1):110-8. PubMed ID: 12859987
    [Abstract] [Full Text] [Related]

  • 13. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
    Nemeikaite-Ceniene A, Dringeliene A, Sarlauskas J, Cenas N.
    Acta Biochim Pol; 2005 Aug 01; 52(4):937-41. PubMed ID: 15940348
    [Abstract] [Full Text] [Related]

  • 14. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
    Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA.
    Mol Pharmacol; 1996 Oct 01; 50(4):728-35. PubMed ID: 8863816
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM, Phillips RM, Lim LE, Bibby MC.
    Biochem Pharmacol; 2000 Apr 01; 59(7):831-7. PubMed ID: 10718341
    [Abstract] [Full Text] [Related]

  • 16. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
    Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P.
    Mol Pharmacol; 2000 Nov 01; 58(5):1146-55. PubMed ID: 11040064
    [Abstract] [Full Text] [Related]

  • 17. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
    Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J, Robson L, Halbert G, Dive C, Ranson M.
    Ann Oncol; 2011 Jul 01; 22(7):1653-1660. PubMed ID: 21378203
    [Abstract] [Full Text] [Related]

  • 18. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
    Hussein D, Holt SV, Brookes KE, Klymenko T, Adamski JK, Hogg A, Estlin EJ, Ward T, Dive C, Makin GW.
    Br J Cancer; 2009 Jul 07; 101(1):55-63. PubMed ID: 19491903
    [Abstract] [Full Text] [Related]

  • 19. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
    Hasinoff BB, Begleiter A.
    Free Radic Res; 2006 Sep 07; 40(9):974-8. PubMed ID: 17015278
    [Abstract] [Full Text] [Related]

  • 20. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
    Park MT, Song MJ, Oh ET, Lee H, Choi BH, Jeong SY, Choi EK, Park HJ.
    Br J Pharmacol; 2011 Jun 07; 163(3):567-85. PubMed ID: 21250978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.